Literature DB >> 804350

Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

M A Goldsmith, M Slavik, S K Carter.   

Abstract

The mouse, dog, and monkey toxicity data on 30 drugs was retrospectively analyzed in comparison with the actual clinical dose schedules used in man. Animal dose schedules were converted to the human schedule and comparisons were made of the human dose versus the large animal toxic dose low, toxic dose high, and lethal dose, the lethal doses for 10% and 90% of normal mice, and the optimal dose in tumor-bearing mice. If the starting dose in Phase 1 clinical trials had been selected by calculating one-third of the toxic dose low (in mg/sq m) in the most sensitive large animal species, 5 of the 30 drugs would have produced significant toxicity in the first patient. The lethal doses for 10 and 90% of normal mice and the optimal dose in L1210-bearing mice were found to offer good quantitative prediction of human toxicity. Determination of a safe and practical starting dose for Phase 1 studies should take into account not only dog and monkey data but also toxicology data in normal and tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 804350

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials.

Authors:  J S Penta; M Rozencweig; A M Guarino; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 2.  Choice of starting dose and escalation for phase I studies of antitumor agents.

Authors:  J S Penta; G L Rosner; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

4.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Iron Overload Resulting from the Chronic Oral Administration of Ferric Citrate Impairs Intestinal Immune and Barrier in Mice.

Authors:  Qihui Luo; Chengjie Lao; Chao Huang; Yu Xia; Wenjing Ma; Wentao Liu; Zhengli Chen
Journal:  Biol Trace Elem Res       Date:  2020-05-28       Impact factor: 3.738

6.  The war on cancer: have we won the battle but lost the war?

Authors:  Rachel Brennan; Sara Federico; Michael A Dyer
Journal:  Oncotarget       Date:  2010-06

7.  Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.

Authors:  J G Supko; L Malspeis
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.

Authors:  Elisabeth I Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

Review 9.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; M P Djavanmard; W Scheithauer; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.